Related Experiment Video
Updated: Apr 8, 2026
08:10
Capture and Release of Viable Circulating Tumor Cells from Blood
Published on: October 28, 2016
9.1K
Sampling circulating tumor cells for clinical benefits: how frequent?
Sai Mun Leong1, Karen M L Tan2, Hui Wen Chua1
1Department of Laboratory Medicine, National University Hospital, Level 3 NUH Main Building, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore.
Journal of Hematology & Oncology
|June 26, 2015
Summary
Infrequent sampling of circulating tumor cells (CTCs) can lead to misleading cancer insights. Highly frequent CTC analysis is crucial for understanding tumor dynamics and improving patient management.
Area of Science:
- Oncology
- Biomarker Discovery
- Cancer Research
Background:
- Circulating tumor cells (CTCs) are vital biomarkers for cancer diagnosis, management, and prognostication.
- Current research often relies on infrequent CTC sampling, assuming gradual changes over time.
- The kinetics of CTC dissemination and molecular changes in patients remain poorly understood.
Purpose of the Study:
- To investigate the impact of sub-optimal CTC sampling on clinical observations.
- To highlight the necessity of frequent CTC sampling for accurate cancer patient monitoring.
- To inform the development of optimal sampling strategies for clinical trials and patient care.
Main Methods:
- Analysis of clinical case studies.
- Development of hypothetical simulation models for CTC kinetics.
- Evaluation of sub-optimal sampling frequencies versus frequent sampling.
Main Results:
- Sub-optimal CTC sampling can result in misleading observations by missing critical CTC spikes.
- Infrequent sampling may lead to inaccurate assessments of tumor dynamics and patient status.
- Clinical consequences can arise from missed transient CTC changes.
Conclusions:
- Highly frequent CTC sampling is essential for understanding dissemination dynamics and molecular changes.
- Optimizing CTC sampling frequency is critical for accurate clinical trial interpretation.
- Improved understanding of CTC kinetics will enhance cancer management strategies and patient outcomes.
